Abstract
Background: Metabolic Syndrome (MetS) is a multifactorial condition characterized by insulin resistance, dyslipidemia, hypertension, and abdominal obesity, which collectively increase the risk of type 2 diabetes mellitus and cardiovascular diseases. Lifestyle modification represents the first-line strategy in its management, whereas pharmacological interventions are complex and typically require long-term polypharmacotherapy. In this context, natural bioactive compounds with pleiotropic effects are gaining increasing attention. Among these, S-allyl cysteine (SAC), the major sulfur-containing compound derived from black garlic, has been identified as a promising candidate due to its well-documented antioxidant and anti-inflammatory properties. Methods: This narrative review examines the pathophysiological mechanisms underlying MetS and summarizes current evidence on the protective role of SAC against key pathological features of this condition, including oxidative stress, inflammation, glucose and lipid dysmetabolism, endothelial dysfunction, and gut microbiota alterations. Results: Preclinical studies indicate that SAC counteracts lipid accumulation, insulin resistance, endothelial dysfunction, and gut dysbiosis through multiple mechanisms, including hydrogen sulfide release, reactive oxygen species scavenging, inhibition of advanced glycation end products, and modulation of metabolic pathways. Conclusions: SAC emerges as a promising nutraceutical for the prevention and management of MetS and its complications. This underscores the broader relevance of nutraceuticals as promising tools in mitigating metabolic dysfunctions and reducing the burden of cardiometabolic diseases.